HR
KYNB

Howe & Rusling’s Kyntra Bio KYNB Stock Holding History

Howe & Rusling’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1
Closed -$1K – 1059
2016
Q2 		$1K Hold
1
– – ﹤0.01% 899
2016
Q1 		$1K Hold
1
– – ﹤0.01% 935
2015
Q4 		$1K Hold
1
– – ﹤0.01% 906
2015
Q3 		$1K Hold
1
– – ﹤0.01% 913
2015
Q2 		$1K Buy
+1
New +$582 ﹤0.01% 953

Other funds holding KYNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Howe & Rusling's KYNB Position: Q3 2016 in Review

Howe & Rusling sold out of Kyntra Bio (KYNB) in Q3 2016, closing a stake of 1 share — an estimated $1K sold.

Howe & Rusling first reported a position in KYNB in Q2 2015 and held it in 5 quarters. The position peaked at $1K in Q2 2016. 133 funds tracked by Wall St. Rank hold KYNB as of Q3 2016.

  • Howe & Rusling reported no remaining Kyntra Bio position as of Q3 2016 after selling out during the quarter.
  • Howe & Rusling sold 1 Kyntra Bio share in Q3 2016, an estimated $1K.
  • Howe & Rusling first reported a position in Kyntra Bio in Q2 2015 and held it in 5 quarters.
  • Howe & Rusling's Kyntra Bio position peaked at $1K in Q2 2016.
  • 133 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2016.

Based on Howe & Rusling's 13F filing for Q3 2016, filed 17 Oct 2016.